Comparative Pharmacology
Head-to-head clinical analysis: TOPICORT versus TOPICORT LP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOPICORT versus TOPICORT LP.
TOPICORT vs TOPICORT LP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing production of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topicort LP (desoximetasone) is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to intracellular glucocorticoid receptors, leading to modulation of gene expression that suppresses inflammatory mediators such as prostaglandins, leukotrienes, and cytokines.
Apply a thin film to the affected skin areas twice daily. Maximum adult dose: 50 g/week. Not for use on the face, axillae, or groin. Do not use under occlusive dressings.
Apply a thin film to the affected skin areas twice daily. Route: topical. Frequency: twice daily.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours for parent drug; clinical effect lasts longer due to receptor binding
Terminal elimination half-life is approximately 2-4 hours after topical application. This short half-life reflects rapid systemic clearance and minimal accumulation with once-daily dosing.
Renal (metabolites): ~75%; Fecal: ~25%
Primarily renal (urinary excretion of metabolites and unchanged drug). Biliary/fecal elimination is minimal, accounting for <5% of the dose.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid